Tesaglitazar vs Glibenclamide Long-Term Extension in Type 2 Diabetes

Phase 3, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs, body weight up to 103 weeks. Started Oct 2005; status: terminated.